Eton Pharmaceuticals, Inc. made a stalking horse bid to acquire Certain assets including the Vistogard and Xuriden from Wellstat Therapeutics Corporation and Wellstat Biologics Corporation for $37 million.

Eton Pharmaceuticals, Inc. (NasdaqGM:ETON) made a stalking horse bid to acquire Certain assets including the Vistogard and Xuriden from Wellstat Therapeutics Corporation and Wellstat Biologics Corporation for $37 million on June 9, 2023. The transaction includes sell-side termination fee of $0.8 million. The deal will be financed through its cash on hand and certain commited financing.

The transaction is subject to the approval of Bankruptcy Court.